Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2017, 161(2):134-143 | DOI: 10.5507/bp.2017.016

Therapeutic monitoring of amiodarone: pharmacokinetics and evaluation of the relationship between effect and dose/concentration

Erika Hrudikova Vyskocilovaa,b, Milan Grundmanna, Jana Duricovaa,b, Ivana Kacirovaa,b
a Department of Clinical Pharmacology, Faculty of Medicine, University of Ostrava, Czech Republic
b Institute of Clinical Pharmacology, Department of Laboratory Diagnostics, University Hospital Ostrava, Czech Republic

Amiodarone is the most effective agent in the therapy of arrhythmias. However, the clinical effect of acute and chronic treatment is unclear and there are differences irrespective of comparable plasma/myocardial amiodarone and its metabolite desethylamiodarone concentations as well. Its unusual pharmacokinetics results in interindividual variation in plasma levels. The association between amiodarone and desethylamiodarone plasma levels and clinical efficacy is difficult to evaluate. This review was carried out to assess whether there is any objective correlation between amiodarone and desethylamiodarone plasma levels and the clinical effect. We summarized the results of relevant studies and clarified the relationship between plasma levels and effect vis á vis the pharmacokinetics and pharmacogenetics of this drug. Certain correlation was seen with oral amiodarone therapy, in others, plasma amiodarone levels were unrelated to therapeutic response and showed no correlation with changes in electrocardiogram or electrophysiological parametres. Several studies show that plasma concentration ranging between 0.5 and 2.5 mg/L appears to be the most effective, others demonstrate no difference between responders and non-responders. One way of interpreting plasma levels is to establish an individual patient´s effective concentration. Therapeutic drug monitoring can contribute to determining optimal concentration.

Keywords: amiodarone, pharmacokinetics, effects, therapeutic drug monitoring

Received: July 27, 2016; Accepted: March 22, 2017; Prepublished online: March 31, 2017; Published: June 14, 2017  Show citation

ACS AIP APA ASA Harvard Chicago IEEE ISO690 MLA NLM Turabian Vancouver
Hrudikova Vyskocilova, E., Grundmann, M., Duricova, J., & Kacirova, I. (2017). Therapeutic monitoring of amiodarone: pharmacokinetics and evaluation of the relationship between effect and dose/concentration. Biomedical papers, 161(2), 134-143. doi: 10.5507/bp.2017.016
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Kumar K, Zimetbaum PJ. Antiarrhythmic drugs 2013: state of the art. Curr Cardiol Rep 2013;15(10):410. doi:10.1007/s11886-013-0410-2 Go to original source... Go to PubMed...
    2. Riva E, Gerna M, Latini R, Giani P, Volpi A, Maggioni A. Pharmacokinetics of amiodarone in man. J Cardiovasc Pharmacol 1982;4(2):264-9. Go to original source... Go to PubMed...
    3. Andreasen F, Agerbaek H, Bjerregaard P, Gøtzsche H. Pharmacokinetics of amiodarone after intravenous and oral administration. Eur J Clin Pharmacol 1981;19(4):293-9. Go to original source... Go to PubMed...
    4. Kashima A, Funahashi M, Fukumoto K et al. Pharmacokinetic characteristics of amiodarone in long-term oral therapy in Japanese population. Biol Pharm Bull 2005;28(10):1934-8. Go to original source... Go to PubMed...
    5. Shiga T, Tanaka T, Irie S, Hagiwara N, Kasanuki H. Pharmacokinetics of intravenous amiodarone and its electrocardiographic effects on healthy Japanese subjects. Heart Vessels 2011;26(3):274-81. doi:10.1007/s00380-010-0047-7 Go to original source... Go to PubMed...
    6. Veronese ME, McLean S, Hendrik R. Plasma protein binding of amiodarone in a patient population: measurement by erythrocyte partitioning and a novel glass-binding method. Br J Clin Pharmacol 1988;26(6):721-31. Go to original source... Go to PubMed...
    7. Nattel S, Talajic M, Fermini B, Roy D. Amiodarone: Pharmacology, Clinical Actions, and Relationships Between Them. J Cardiovasc Electrophysiol 1992;3(3):266-80. Go to original source...
    8. Holt DW, Tucker GT, Jackson PR, Storey GC. Amiodarone pharmacokinetics. Am Heart J 1983;106(4 Pt 2):840-7. Go to original source... Go to PubMed...
    9. Pollak PT, Bouillon T, Shafer SL. Population pharmacokinetics of long-term oral amiodarone therapy. Clin Pharmacol Ther 2000;67(6):642-52. Go to original source... Go to PubMed...
    10. Rotmensch HH, Swanson BN, Greenspon AJ, Shoshani D, Greenspan AM. Amiodarone: individualizing dosage with serum concentrations. Pacing Clin Electrophysiol 1983;6(6):1327-35. Go to original source... Go to PubMed...
    11. Heger JJ, Prystowsky EN, Zipes DP. Relationships between amiodarone dosage, drug concentrations, and adverse side effects. Am Heart J 1983;106(4 Pt 2):931-5. Go to original source... Go to PubMed...
    12. Anastasiou-Nana MI, Nanas JN, Alexopoulos G, Karli JN, Margari ZJ, Agapitos E, Patsi EN, Stamatelopoulos SF. Amiodarone concentration in human myocardium after rapid intravenous administration. Cardiovasc Drugs Ther 1999;13(3):265-70. Go to original source... Go to PubMed...
    13. Robson' DJ, Jeeva Raj MV, Storey CAG, Holt DW. Use of amiodarone during pregnancy. Postgrad Med J 1985;61:75-7. doi:10.1136/pgmj.61.711.75 Go to original source... Go to PubMed...
    14. Anastasiou-Nana M, Levis GM, Moulopoulos S. Pharmacokinetics of amiodarone after intravenous and oral administration. Int J Clin Pharmacol Ther Toxicol 1982;20(11):524-9.
    15. Siddoway LA, McAllister CB, Wilkinson GR, Roden DM, Woosley RL. Amiodarone dosing: a proposal based on its pharmacokinetics. Am Heart J 1983;106(4 Pt 2):951-6. Go to original source... Go to PubMed...
    16. Fukumoto K, Kobayashi T, Tachibana K, Kato R, Tanaka K, Komamura K, Kamakura S, Kitakaze M, Ueno K. Effect of amiodarone on the serum concentration/dose ratio of metoprolol in patients with cardiac arrhythmia. Drug Metab Pharmacokinet 2006;21(6):501-5. Go to original source... Go to PubMed...
    17. Ha HR, Bigler L, Binder M, Kozlik P, Stieger B, Hesse M, Altorfer HR, Follath F. Metabolism of amiodarone (part I): identification of a new hydroxylated metabolite of amiodarone. Drug Metab Dispos 2001;29(2):152-8.
    18. Ohyama K, Nakajima M, Nakamura S, Shimada N, Yamazaki H, Yokoi T. A significant role of human cytochrome P450 2C8 in amiodarone N-deethylation: an approach to predict the contribution with relative activity factor. Drug Metab Dispos 2000;28(11):1303-10.
    19. Elsherbin ME, El-Kadi AO, Brocks DR. The metabolism of amiodarone by various CYP isoenzymes of human and rat, and the inhibitory influence of ketoconazole. J Pharm Pharm Sci 2008;11(1):147-59. Go to original source... Go to PubMed...
    20. Soyama A, Hanioka N, Saito Y, Murayama N, Ando M, Ozawa S, Sawada J. Amiodarone N-deethylation by CYP2C8 and its variants, CYP2C8*3 and CYP2C8 P404A. Pharmacol Toxicol 2002;91(4):174-8. Go to original source... Go to PubMed...
    21. García-Martín E, Martínez C, Ladero JM, Agúndez JA. Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals. Mol Diagn Ther 2006;10(1):29-40. Go to original source... Go to PubMed...
    22. Latini R, Tognoni G, Kates RE. Clinical pharmacokinetics of amiodarone. Clin Pharmacokinet 1984;9(2):136-56. Go to original source... Go to PubMed...
    23. Harris L, Hind CR, McKenna WJ, Savage C, Krikler SJ, Storey GC, Holt DW. Renal elimination of amiodarone and its desethyl metabolite. Postgrad Med J 1983;59(693):440-2. Go to original source... Go to PubMed...
    24. Chow MS. Intravenous amiodarone: pharmacology, pharmacokinetics, and clinical use. Ann Pharmacother 1996;30(6):637-43. Go to original source... Go to PubMed...
    25. Ikeda N, Nademanee K, Kannan R, Singh BN. Electrophysiologic effects of amiodarone: experimental and clinical observation relative to serum and tissue drug concentrations. Am Heart J 1984;108(4 Pt 1):890-8. Go to original source... Go to PubMed...
    26. Kodama I, Kamiya K, Toyama J. Cellular electropharmacology of amiodarone. Cardiovasc Res 1997;35(1):13-29. Go to original source... Go to PubMed...
    27. Charlier R. Cardiac actions in the dog of a new antagonist of adrenergic excitation which does not produce competitive blockade of adrenoceptors. Br J Pharmacol 1970;39(4):668-74. Go to original source... Go to PubMed...
    28. Kodama I, Kamiya K, Honjo H, Toyama J. Acute and chronic effects of amiodarone on mammalian ventricular cells. Jpn Heart J 1996;37(5):719-30. Go to original source... Go to PubMed...
    29. Mori K, Saito T, Masuda Y, Nakaya H. Effects of class III antiarrhythmic drugs on the Na(+)-activated K+ channels in guinea-pig ventricular cells. Br J Pharmacol 1996;119(1):133-41. Go to original source... Go to PubMed...
    30. Yabek SM, Kato R, Singh BN. Acute effects of amiodarone on the electrophysiologic properties of isolated neonatal and adult cardiac fibers. J Am Coll Cardiol 1985;5(5):1109-15. Go to original source... Go to PubMed...
    31. Goupil N and Lenfant J. The effects of amiodarone on the sinus node activity of the rabbit heart. Eur J Pharmacol 1976;39(1):23-31. Go to original source... Go to PubMed...
    32. Pickoff AS, Singh S, Flinn CJ, Torres E, Ezrin AM, Gelband H. Dose-dependent electrophysiologic effects of amiodarone in the immature canine heart. Am J Cardiol 1983;52(5):621-5. Go to original source... Go to PubMed...
    33. Nattel S, Talajic M, Quantz M, DeRoode M. Frequency-dependent effects of amiodarone on atrioventricular nodal function and slow-channel action potentials: evidence for calcium channel-blocking activity. Circulation 1987;76(2):442-9. Go to original source... Go to PubMed...
    34. Hamer AW, Mandel WJ, Zaher CA, Karagueuzin HS, Peter T. The electrophysiologic basis for the use of amiodarone for treatment of cardiac arrhythmias. Pacing Clin Electrophysiol 1983;6(4):784-94. Go to original source... Go to PubMed...
    35. Cahoon W Jr, Flattery MP, Hess ML. Amiodarone: development, clinical indications, and safety. Prog Cardiovasc Nurs 2007;22(3):173-6. Go to original source... Go to PubMed...
    36. Van Herendael H and Dorian P. Amiodarone for the treatment and prevention of ventricular fibrillation and ventricular tachycardia.Vasc Health Risk Manag 2010;6(9):465-7. Go to original source...
    37. Nattel S. Pharmacodynamic studies of amiodarone and its active N-desethyl metabolite. J Cardiovasc Pharmacol 1986;8(4):771-7.
    38. Talajic M, DeRoode MR, Nattel S. Comparative electrophysiologic effects of intravenous amiodarone and desethylamiodarone in dogs: evidence for clinically relevant activity of the metabolite. Circulation 1987;75(1):265-71. Go to original source... Go to PubMed...
    39. Varbiro G, Toth A, Tapodi A, Bognar Z, Veres B, Sumegi B, Gallyas F Jr. Protective effect of amiodarone but not N-desethylamiodarone on postischemic hearts through the inhibition of mitochondrial permeability transition. J Pharmacol Exp Ther 2003;307(2):615-25. Go to original source... Go to PubMed...
    40. Wolbrette DL. Risk of proarrhythmia with class III antiarrhythmic agents: sex-based differences and other issues. Am J Cardiol 2003;91(6A):39D-44D. Go to original source... Go to PubMed...
    41. Munoz A, Karila P, Gallay P, Zettelmeier F, Messner P, Mery M, Grolleau R. A randomized hemodynamic comparison of intravenous amiodarone with and without Tween 80. Eur Heart J 1988;9(2):142-8. Go to original source... Go to PubMed...
    42. Scheinman MM, Levine JH, Cannom DS, Friehling T, Kopelman HA, Chilson DA, Platia EV, Wilber DJ, Kowey PR. Dose-ranging study of intravenous amiodarone in patients with life-threatening ventricular tachyarrhythmias. The Intravenous Amiodarone Multicenter Investigators Group. Circulation 1995;92(11):3264-72. Go to original source... Go to PubMed...
    43. Pollak PT. How Toxic is Amiodarone to the Liver? J Gastrointestin Liver Dis 2010;19(1):11-3.
    44. Shukla R, Jowett NT, Thompson DR, Pohl JE. Side effects with amiodarone therapy. Postgrad Med J 1994;70(825):492-8. Go to original source... Go to PubMed...
    45. Schwaiblmair M, Berghaus T, Haeckel T, Wagner T, von Scheidt W. Amiodarone-induced pulmonary toxicity: an under-recognized and severe adverse effect? Clin Res Cardiol 2010;99(11):693-700. doi:10.1007/s00392-010-0181-3 Go to original source... Go to PubMed...
    46. Werner D, Wuttke H, Fromm MF, Schaefer S, Eschenhagen T, Brune K, Daniel WG, Werner U. Effect of amiodarone on the plasma levels of metoprolol. Am J Cardiol 2004;94(10):1319-21. Go to original source... Go to PubMed...
    47. Nattel S, Davies M, Quantz M. The antiarrhythmic efficacy of amiodarone and desethylamiodarone, alone and in combination, in dogs with acute myocardial infarction. Circulation 1988;77(1):200-8. Go to original source... Go to PubMed...
    48. Nanas JN, Mason JW. Pharmacokinetics and regional electrophysiological effects of intracoronary amiodarone administration. Circulation 1995;91(2):451-61. Go to original source... Go to PubMed...
    49. Gambhir DS, Bhargava M, Nair M, Arora R, Khalilullah M. Comparison of electrophysiologic effects and efficacy of single-dose intravenous and long-term oral amiodarone therapy in patients with AV nodal reentrant tachycardia. Indian Heart J 1996;48(2):133-7.
    50. Saksena S, Rothbart ST, Shah Y, Cappello G. Clinical efficacy and electropharmacology of continuous intravenous amiodarone infusion and chronic oral amiodarone in refractory ventricular tachycardia. Am J Cardiol 1984;54(3):347-52. Go to original source... Go to PubMed...
    51. Kowey PR, Levine JH, Herre JM, Pacifico A, Lindsay BD, Plumb VJ, Janosik DL, Kopelman HA, Scheinman MM. Randomized, double-blind comparison of intravenous amiodarone and bretylium in the treatment of patients with recurrent, hemodynamically destabilizing ventricular tachycardia or fibrillation. The Intravenous Amiodarone Multicenter Investigators Group. Circulation 1995;92(11):3255-63. Go to original source... Go to PubMed...
    52. Levine JH, Massumi A, Scheinman MM, Winkle RA, Platia EV, Chilson DA, Gomes A, Woosley RL. Intravenous amiodarone for recurrent sustained hypotensive ventricular tachyarrhythmias. Intravenous Amiodarone Multicenter Trial Group. J Am Coll Cardiol 1996;27(1):67-75. Go to original source... Go to PubMed...
    53. Giani P, Maggioni AP, Volpi A, Cavalli A, Latini R, Neyroz P, Riva E, D'Aranno V. Blood levels and electrophysiological effects of intravenous amiodarone in patients with junctional reciprocating tachycardia. Preliminary observations. Acta Cardiol 1984;39(1):9-17.
    54. Escoubet B, Coumel P, Poirier JM, Maison-Blanche P, Jaillon P, Leclercq JF, Menasche P, Cheymol G, Piwnica A, Lagier G, et al. Suppression of arrhythmias within hours after a single oral dose of amiodarone and relation to plasma and myocardial concentrations. Am J Cardiol 1985;55(6):696-702. Go to original source... Go to PubMed...
    55. Nielsen KD and Møller S. Amiodarone for rapid cardioversion of chronic atrial tachyarrhythmia? Pharmacol Toxicol 2000;86(6):283-6. Go to original source... Go to PubMed...
    56. Tieleman RG, Gosselink AT, Crijns HJ, van Gelder IC, van den Berg MP, de Kam PJ, van Gilst WH, Lie KI. Efficacy, safety, and determinants of conversion of atrial fibrillation and flutter with oral amiodarone. Am J Cardiol 1997;79(1):53-7. Go to original source... Go to PubMed...
    57. Kaski JC, Girotti LA, Messuti H, Rutitzky B, Rosenbaum MB. Long-term management of sustained, recurrent, symptomatic ventricular tachycardia with amiodarone. Circulation 1981;64(2):273-9. Go to original source... Go to PubMed...
    58. Mostow ND, Vrobel TR, Noon D, Rakita L. Rapid suppression of complex ventricular arrhythmias with high-dose oral amiodarone. Circulation 1986;73:1231-8. Go to original source... Go to PubMed...
    59. Greenberg ML, Lerman BB, Haines DE, Baron JA, Dimarco JP. Stability of electrophysiological parameters after acute amiodarone loading: implications for patient management. Pacing Clin Electrophysiol 1989;12(7 Pt 1):1038-43. Go to original source... Go to PubMed...
    60. Rotmensch HH, Belhassen B, Swanson BN, Shoshani D, Spielman SR, Greenspon AJ, Greenspan AM, Vlasses PH, Horowitz LN. Steady- state serum amiodarone concentrations: relationships with antiarrhythmic efficacy and toxicity. Ann Intern Med 1984;101(4):462-9. Go to original source... Go to PubMed...
    61. Haffajee CI, Love JC, Canada AT, Lesko LJ, Asdourian G, Alpert JS. Clinical pharmacokinetics and efficacy of amiodarone for refractory tachyarrhythmias. Circulation 1983;67(6):1347-55. Go to original source... Go to PubMed...
    62. Mostow ND, Rakita L, Vrobel TR, Noon DL, Blumer J. Amiodarone: correlation of serum concentration with suppression of complex ventricular ectopic activity. Am J Cardiol 1984;54(6):569-74. Go to original source... Go to PubMed...
    63. Connolly SJ, Gupta RN, Hoffert D, Roberts RS. Concentration response relationships of amiodarone and desethylamiodarone. Am Heart J 1988;115(6):1208-13. Go to original source... Go to PubMed...
    64. Saksena S, Rothbart ST, Cappello G. Chronic effects of amiodarone in patients with refractory ventricular tachycardia. Int J Cardiol 1983;3(3):339-52. Go to original source... Go to PubMed...
    65. Greenberg ML, Lerman BB, Shipe JR, Kaiser DL, DiMarco JP. Relation between amiodarone and desethylamiodarone plasma concentrations and electrophysiologic effects, efficacy and toxicity. J Am Coll Cardiol 1987;9(5):1148-55. Go to original source... Go to PubMed...
    66. Debbas NM, du Cailar C, Bexton RS, Demaille JG, Camm AJ, Puech P. The QT interval: a predictor of the plasma and myocardial concentrations of amiodarone. Br Heart J 1984;51(3):316-20. Go to original source... Go to PubMed...
    67. Ward DE, Camm AJ, Spurrell RA. Clinical antiarrhythmic effects of amiodarone in patients with resistant paroxysmal tachycardias. Br Heart J 1980;44(1):91-5. Go to original source... Go to PubMed...
    68. Kavesh NG, Olsovsky MR, Freudenberger RS, Conte JV, Peters RW, Shorofsky SR, Gold MR. Intravenous amiodarone suppression of electrical storm refractory to chronic oral amiodarone. Pacing Clin Electrophysiol 1999;22(4 Pt 1):665-7. Go to original source... Go to PubMed...
    69. Campbell TJ and Williams KM. Therapeutic drug monitoring: antiarrhythmic drugs. Br J Clin Pharmacol 2001;52(S1):21S-34S. Go to original source... Go to PubMed...
    70. Robinson K, Johnston A, Walker S, Mulrow J, Holt D, McKenna W. Stability of plasma amiodarone levels during chronic oral therapy. Cardiovasc Drugs Ther 1990;4(2):529-30. Go to original source... Go to PubMed...
    71. Maling TJ, Siebers RW, Burgess CD, Taylor C, Purdie G. Individual variability of amiodarone distribution in plasma and erythrocytes: implications for therapeutic monitoring. Ther Drug Monit 1989;11(2):121-6. Go to original source... Go to PubMed...
    72. Kotake T, Takada M, Goto T, Komamura K, Kamakura S, Morishita H. Serum amiodarone and desethylamiodarone concentrations following nasogastric versus oral administration. J Clin Pharm Ther 2006;31(3):237-43. Go to original source... Go to PubMed...
    73. Candinas R, Frielingsdorf J, Ha HR, Carrel T, Turina M, Follath F. Myocardial amiodarone concentrations after short- and long-term treatment in patients with end-stage heart failure. Eur J Clin Pharmacol 1998;53(5):331-6. Go to original source... Go to PubMed...
    74. Kaplan LJ, Cappaert WE. Amiodarone-induced corneal deposits. Ann Ophthalmol 1984;16(8):762-6.
    75. Rakita L, Sobol SM, Mostow N, Vrobel T. Amiodarone pulmonary toxicity. Am Heart J 1983;106(4 Pt 2):906-16. Go to original source... Go to PubMed...
    76. Burton ME. Applied pharmacokinetics: principles of therapeutic drug monitoring. 4th ed. Baltimore: Lippincott Williams; 2006 p. 446-57.

    Return to the content